Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$187.91
+0.1%
$195.06
$134.30
$214.51
$52.86B0.422.82 million shs1.95 million shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$1,096.33
-0.9%
$983.33
$653.23
$1,125.00
$326.39B1.32.32 million shs2.06 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$61.00
+2.8%
$50.93
$22.28
$67.74
$23.55B1.059.18 million shs6.81 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
+2.34%-1.14%-6.43%-4.70%+26.17%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
+0.52%+2.58%+10.88%+32.24%+72.60%
Moderna, Inc. stock logo
MRNA
Moderna
-7.21%+13.85%+26.60%+15.60%+129.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$187.91
+0.1%
$195.06
$134.30
$214.51
$52.86B0.422.82 million shs1.95 million shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$1,096.33
-0.9%
$983.33
$653.23
$1,125.00
$326.39B1.32.32 million shs2.06 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$61.00
+2.8%
$50.93
$22.28
$67.74
$23.55B1.059.18 million shs6.81 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
+2.34%-1.14%-6.43%-4.70%+26.17%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
+0.52%+2.58%+10.88%+32.24%+72.60%
Moderna, Inc. stock logo
MRNA
Moderna
-7.21%+13.85%+26.60%+15.60%+129.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
3.04
Buy$221.3717.81% Upside
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.39
Hold$949.55-13.39% Downside
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$36.60-40.00% Downside

Current Analyst Ratings Breakdown

Latest FANG, GS, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Boost Price TargetNeutral$930.00 ➝ $1,100.00
6/22/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Set Price Target$212.00
6/22/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Set Price TargetNeutralBuy$212.00
6/21/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
UpgradeHoldStrong-Buy
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
6/12/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Set Price Target$900.00
6/12/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Boost Price TargetNeutral$826.00 ➝ $900.00
6/10/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Reiterated RatingStrong-Buy$249.00
6/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$32.00 ➝ $34.00
5/28/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
DowngradeStrong-BuyHold
(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$15.03B3.52$31.85 per share5.90$150.03 per share1.25
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$60.45B5.35$64.53 per share16.99$366.15 per share2.99
Moderna, Inc. stock logo
MRNA
Moderna
$2.20B10.98N/AN/A$22.14 per share2.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$1.66B$0.86218.5010.98N/A1.87%7.76%4.67%8/3/2026 (Estimated)
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$17.18B$54.7220.0416.541.4314.13%16.53%0.97%7/14/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)

Latest FANG, GS, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/14/2026Q2 2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$13.75N/AN/AN/A$15.73 billionN/A
5/4/2026Q1 2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$3.74$4.23+$0.49$0.08$3.83 billion$4.24 billion
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/13/2026Q1 2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$15.92$17.55+$1.63$17.55$16.66 billion$17.23 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$4.402.34%+21.67%511.63%7 Years
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$18.001.64%+22.87%32.89%13 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest FANG, GS, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/13/2026
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$4.501.72%6/1/20266/1/20266/29/2026
4/29/2026
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
quarterly$1.102.2%5/14/20265/14/20265/21/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.31
0.56
0.55
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.89
0.63
0.63
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35

Institutional Ownership

CompanyInstitutional Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
90.01%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
71.21%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.64%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.55%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
1,762281.31 million279.51 millionOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
47,400295.01 million293.38 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable

Recent News About These Companies

Moderna snaps after six-session winning streak
FDA panel backs 1st mRNA flu vaccine
Should You Buy Moderna Before Aug. 5?
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway
Moderna's mRNA flu vaccine backed by FDA advisers
Moderna, Inc. $MRNA Shares Sold by Tobam
Promising Biotech Stocks To Follow Today - June 19th
FDA panel supports first mRNA-based flu vaccine

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Diamondback Energy stock logo

Diamondback Energy NASDAQ:FANG

$187.91 +0.11 (+0.06%)
Closing price 04:00 PM Eastern
Extended Trading
$187.70 -0.21 (-0.11%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Diamondback Energy, Inc., an independent oil and natural gas company, acquires, develops, explores, and exploits unconventional, onshore oil and natural gas reserves in the Permian Basin in West Texas. It focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. The company also owns and operates midstream infrastructure assets, in the Midland and Delaware Basins of the Permian Basin. Diamondback Energy, Inc. was founded in 2007 and is headquartered in Midland, Texas.

The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$1,096.33 -10.04 (-0.91%)
Closing price 03:58 PM Eastern
Extended Trading
$1,092.36 -3.97 (-0.36%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$61.00 +1.65 (+2.78%)
Closing price 04:00 PM Eastern
Extended Trading
$60.98 -0.02 (-0.04%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.